文献速递脊柱关节炎

双靶向中和IL-17F与IL-17A可阻断炎症驱动的人骨膜细胞成骨分化

Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells.
PubMed 文献 · RMD Open · 2020-01-01

该研究利用人骨膜来源细胞(hPDC)成骨分化模型,结合重组IL-17细胞因子、T细胞上清及强直性脊柱炎(AS)患者血清,发现IL-17A和IL-17F均促进成骨分化,而双靶向中和IL-17A与IL-17F较单独中和任一细胞因子更深度阻断成骨,AS患者血清诱导的成骨承诺同样被双中和所消除。

要点

  • 重组IL-17A和IL-17F均可促进hPDC成骨分化。
  • 双靶向中和IL-17A与IL-17F较单靶向更深度阻断Th17或γδ-T细胞上清诱导的成骨。
  • AS患者血清可诱导成骨承诺,双中和IL-17A与IL-17F可消除该效应。

核心结论

  • IL-17A和IL-17F可增强hPDC的体外成骨分化和骨形成,双靶向中和二者可能成为预防病理性骨形成的治疗策略。

研究设计与样本

  • 研究采用仿生人骨膜来源细胞(hPDC)成骨分化模型,结合重组IL-17细胞因子、T细胞上清或AS患者血清,并使用IL-17A、IL-17F及bimekizumab单克隆抗体阻断IL-17细胞因子作用。

主要发现

  • 重组IL-17A和IL-17F对hPDC分化具有促骨生成作用。
  • Th17或γδ-T细胞上清可强力刺激体外骨形成,双靶向抑制IL-17A和IL-17F较单独中和IL-17A或IL-17F更深度阻断该效应。
  • 成骨阻断可能与Wnt拮抗剂DKK1表达增加有关。
  • AS患者血清可诱导成骨承诺,双靶向中和IL-17A和IL-17F可消除该效应。

临床怎么用

  • 在AS等IL-17相关疾病中,双靶向中和IL-17A和IL-17F可能较单靶向更有效阻断炎症驱动的病理性骨形成。

局限性

  • 研究为体外hPDC模型,结论需进一步体内验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the role of IL-17 in bone pathology is poorly understood. This study aimed to investigate IL-17 signalling in the context of pathological bone formation. METHODS: A biomimetic human periosteum-derived cell (hPDC) model of osteogenic differentiation was used in combination with recombinant IL-17 cytokines, T-cell supernatants or serum from patients with AS. IL-17A, IL-17F and bimekizumab monoclonal antibodies were used to block IL-17 cytokine action. RESULTS: Recombinant IL-17A and IL-17F are pro-osteogenic with respect to hPDC differentiation. T helper 17 or γδ-T cell supernatants also potently stimulated in vitro bone formation, which was blocked deeper by dual inhibition of IL-17A and IL-17F than by neutralisation of IL-17A or IL-17F individually. Osteogenic blockade may be due to an increase in expression of the Wnt antagonist DKK1. Interestingly, osteocommitment was also induced by serum obtained from patients with AS, which was also abrogated by dual neutralisation of IL-17A and IL-17F. CONCLUSIONS: These data show for the first time that IL-17A and IL-17F enhance in vitro osteogenic differentiation and bone formation from hPDCs, inhibition of which may offer an attractive therapeutic strategy to prevent pathological bone formation.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Shah M, Maroof A, Gikas P, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020. PMID: 32723833. doi:10.1136/rmdopen-2020-001306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。